Cardiac failure+1
RecruitingA study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction
A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction
- Disease:Cardiac failureLeft ventricular dysfunction
- Substances:Finerenone
Austria- Participants:0–17 years · 18–64 years
- Substances:Finerenone
- Sponsor:Bayer AG









